These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38709422)

  • 1. Past, Present, and Future Therapeutic Strategies for NF-1-Associated Tumors.
    Na B; Shah SR; Vasudevan HN
    Curr Oncol Rep; 2024 Jun; 26(6):706-713. PubMed ID: 38709422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.
    Williams KB; Largaespada DA
    Genes (Basel); 2020 Apr; 11(5):. PubMed ID: 32353955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
    Gottfried ON; Viskochil DH; Couldwell WT
    Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
    Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
    Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging therapeutic targets for neurofibromatosis type 1.
    Walker JA; Upadhyaya M
    Expert Opin Ther Targets; 2018 May; 22(5):419-437. PubMed ID: 29667529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
    Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofibromin Deficiency Causes Epidermal Growth Factor Receptor Upregulation through the Activation of Ras/ERK/SP1 Signaling Pathway in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheet Tumor.
    Park GH; Lee SJ; Lee CG; Kim J; Park E; Jeong SY
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurofibromatosis 1.
    Lynch TM; Gutmann DH
    Neurol Clin; 2002 Aug; 20(3):841-65. PubMed ID: 12432832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
    Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced pharmacological therapies for neurofibromatosis type 1-related tumors.
    Foiadelli T; Naso M; Licari A; Orsini A; Magistrali M; Trabatti C; Luzzi S; Mosconi M; Savasta S; Marseglia GL
    Acta Biomed; 2020 Jun; 91(7-S):101-114. PubMed ID: 32608378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The promise of signal transduction in genetically driven sarcomas of the nerve.
    Kim A; Pratilas CA
    Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway.
    Feldkamp MM; Angelov L; Guha A
    Surg Neurol; 1999 Feb; 51(2):211-8. PubMed ID: 10029430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1.
    Chai G; Liu N; Ma J; Li H; Oblinger JL; Prahalad AK; Gong M; Chang LS; Wallace M; Muir D; Guha A; Phipps RJ; Hock JM; Yu X
    Cancer Sci; 2010 Sep; 101(9):1997-2004. PubMed ID: 20550523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.
    Ratner N; Miller SJ
    Nat Rev Cancer; 2015 May; 15(5):290-301. PubMed ID: 25877329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofibromatosis type 1 (NF1): diagnosis and management.
    Ferner RE; Gutmann DH
    Handb Clin Neurol; 2013; 115():939-55. PubMed ID: 23931823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurological malignancies in neurofibromatosis type 1.
    Eoli M; Saletti V; Finocchiaro G
    Curr Opin Oncol; 2019 Nov; 31(6):554-561. PubMed ID: 31436563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease.
    Abramowicz A; Gos M
    Dev Period Med; 2014; 18(3):297-306. PubMed ID: 25182393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors.
    Wang J; Pollard K; Calizo A; Pratilas CA
    Cancer Res; 2021 Feb; 81(3):747-762. PubMed ID: 33203698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor microenvironment and neurofibromatosis type I: connecting the GAPs.
    Le LQ; Parada LF
    Oncogene; 2007 Jul; 26(32):4609-16. PubMed ID: 17297459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development.
    Shin J; Padmanabhan A; de Groh ED; Lee JS; Haidar S; Dahlberg S; Guo F; He S; Wolman MA; Granato M; Lawson ND; Wolfe SA; Kim SH; Solnica-Krezel L; Kanki JP; Ligon KL; Epstein JA; Look AT
    Dis Model Mech; 2012 Nov; 5(6):881-94. PubMed ID: 22773753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.